Legal Representation
Attorney
William P. Dickinson III
USPTO Deadlines
Next Deadline
175 days remaining
NOA E-Mailed - SOU Required
Due Date
July 27, 2026
Extension Available
Until January 27, 2027
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 27, 2026 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 21, 2025 | ETOP | T | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | Loading... |
| Oct 21, 2025 | CHPB | I | POST PUBLICATION AMENDMENT - ENTERED | Loading... |
| Oct 14, 2025 | APET | A | ASSIGNED TO PETITION STAFF | Loading... |
| Sep 11, 2025 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| Sep 5, 2025 | EPPA | I | TEAS POST PUBLICATION AMENDMENT RECEIVED | Loading... |
| Aug 12, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 12, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 6, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 3, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jun 24, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jun 24, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 24, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 29, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Mar 29, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Mar 29, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 28, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 27, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 23, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Diagnostic kits consisting primarily of reagents, namely, PCR reagents used to detect and measure levels of RNA with mutations
and normal copies of certain genes in human tumors, for targeting breast, hematological, colorectal, ovarian, head and neck, or
lung cancer or PROS (PIK3CA-related overgrowth syndrome) treatment eligibility, clinical prognosis determination or clinical
follow-up
Class 010
PCR reagents used to detect and measure levels of RNA with mutations and normal copies of certain genes in human tumors, for
targeting breast, hematological, colorectal, ovarian, head and neck, or lung cancer or PROS (PIK3CA-related overgrowth
syndrome) treatment eligibility, clinical prognosis determination or clinical follow-up
Class 042
Software as a service (SAAS) services featuring software for providing RNA analysis, for providing comprehensive understanding
of an individual's genetic profile, and for enabling healthcare providers to make informed decisions about tailored treatment
options, for targeting breast, hematological, colorectal, ovarian, head and neck, or lung cancer or PROS (PIK3CA-related
overgrowth syndrome) treatment eligibility, clinical prognosis determination or clinical follow-up
Additional Information
Pseudo Mark
EXPRESS PIK
Classification
International Classes
005
010
042